No Image Available

Leucovorin tablets/Capsule

Form: Tablet/Capsules

Strength: 15 mg, 50 mg

Reference Brands: Folvite(US & EU)

Category: Blood Disorder

Leucovorin tablets, marketed as Folvite, are approved in both the US by the FDA and in the EU via EMA for folate supplementation, chemotherapy support, and toxicity mitigation. Regulatory approval requires a comprehensive dossier including manufacturing details, clinical efficacy, safety data, and pharmacovigilance plans. In the US, FDA review involves detailed assessment of clinical and manufacturing information, while the EMA ensures compliance with regional standards. For expert guidance on dossier preparation, regulatory strategies, and market access, visit PharmaTradz. Ensuring regional compliance is vital for the safe and effective use of leucovorin tablets worldwide, supporting optimal patient outcomes in oncology and folate deficiency management.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder

Strength: 500 units, 1000 units, and 2500 units

Form: Lyophilized Powder (Reconstituted for IV infusion)

Reference Brands: FEIBA(US)

View Details Get Enquiry
Prothrombin Complex Concentrate (PCC) injection

Strength: 250 IU to 300 IU

Form: Injection

Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)

View Details Get Enquiry
Mesna Injection

Strength: 100 mg/mL

Form: Injection

Reference Brands: Mesnex(US)

View Details Get Enquiry
Pegfilgrastim injection

Strength: 6 mg per single-use syringe

Form: Injection

Reference Brands: Neulasta, Pelgraz(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.